SI1745295T1 - Metode, sestavljanje in preizkuĺ anje spojine za zaviranje tvorbe proteina amiloid-beta - Google Patents
Metode, sestavljanje in preizkuĺ anje spojine za zaviranje tvorbe proteina amiloid-betaInfo
- Publication number
- SI1745295T1 SI1745295T1 SI200531166T SI200531166T SI1745295T1 SI 1745295 T1 SI1745295 T1 SI 1745295T1 SI 200531166 T SI200531166 T SI 200531166T SI 200531166 T SI200531166 T SI 200531166T SI 1745295 T1 SI1745295 T1 SI 1745295T1
- Authority
- SI
- Slovenia
- Prior art keywords
- amyloid
- beta
- gpcr
- compositions
- methods
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title abstract 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 238000003556 assay Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000014616 translation Effects 0.000 title 1
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 abstract 2
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 abstract 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 238000000423 cell based assay Methods 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000020978 protein processing Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56366104P | 2004-04-20 | 2004-04-20 | |
| PCT/EP2005/004325 WO2005103713A2 (en) | 2004-04-20 | 2005-04-20 | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
| EP05744241A EP1745295B1 (en) | 2004-04-20 | 2005-04-20 | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1745295T1 true SI1745295T1 (sl) | 2011-01-31 |
Family
ID=35197590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200531166T SI1745295T1 (sl) | 2004-04-20 | 2005-04-20 | Metode, sestavljanje in preizkuĺ anje spojine za zaviranje tvorbe proteina amiloid-beta |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7429459B2 (enExample) |
| EP (3) | EP2267458A3 (enExample) |
| JP (1) | JP4890442B2 (enExample) |
| AT (1) | ATE483981T1 (enExample) |
| CA (1) | CA2605574A1 (enExample) |
| DE (1) | DE602005023976D1 (enExample) |
| DK (1) | DK1745295T3 (enExample) |
| ES (1) | ES2353604T3 (enExample) |
| SI (1) | SI1745295T1 (enExample) |
| WO (1) | WO2005103713A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1745295T3 (da) * | 2004-04-20 | 2011-01-31 | Galapagos Nv | Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein |
| NZ575804A (en) * | 2006-09-13 | 2012-01-12 | Univ Columbia | Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass |
| GB0700645D0 (en) * | 2007-01-12 | 2007-02-21 | Eisai London Res Lab Ltd | Targets for disease therapy |
| US7968524B2 (en) * | 2007-05-15 | 2011-06-28 | Helicon Therapeutics, Inc. | Methods of enhancing long term memory formation by inhibition of Gpr12 |
| AU2008254907A1 (en) * | 2007-05-15 | 2008-11-27 | Helicon Therapeutics, Inc. | Methods of identifying genes involved in memory formation using small interfering RNA(siRNA) |
| JP5049713B2 (ja) * | 2007-09-14 | 2012-10-17 | 株式会社コナミデジタルエンタテインメント | ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置 |
| EP2440934B1 (en) * | 2009-06-08 | 2014-07-16 | Vib Vzw | Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation |
| WO2011102901A1 (en) * | 2010-02-20 | 2011-08-25 | Ebiotec (Euroespes Biotechnology) | Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphingosine-1-phosphate |
| US20130331330A1 (en) * | 2012-06-08 | 2013-12-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase |
| US20150065376A1 (en) * | 2013-08-12 | 2015-03-05 | Holger Knaut | Expression constructs encoding g protein coupled receptors and methods of use thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| JPH07509133A (ja) | 1992-07-17 | 1995-10-12 | リボザイム・ファーマシューティカルズ・インコーポレイテッド | 動物疾患の処置のための方法および剤 |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| US5998164A (en) | 1995-03-30 | 1999-12-07 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein coupled receptor GPRZ |
| US6090575A (en) | 1995-03-30 | 2000-07-18 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein coupled receptor GPR1 |
| AU2236895A (en) | 1995-03-30 | 1996-10-16 | Human Genome Sciences, Inc. | Human g-protein coupled receptors |
| US6653086B1 (en) * | 1998-04-14 | 2003-11-25 | Arena Pharmaceuticals, Inc. | Endogenous constitutively activated G protein-coupled orphan receptors |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| US6420563B1 (en) | 1998-07-31 | 2002-07-16 | Arena Pharmaceuticals, Inc. | Small molecule modulators of G protein-coupled receptor six |
| CN1364167A (zh) | 1999-02-26 | 2002-08-14 | 阿瑞那制药公司 | G蛋白偶联受体6的小分子调节剂 |
| JP2003518628A (ja) * | 1999-12-10 | 2003-06-10 | アストラゼネカ アクチボラグ | 化合物 |
| WO2001084158A1 (en) * | 2000-05-03 | 2001-11-08 | Astrazeneca Ab | Use of the g protein coupled receptor gpr3 to identify appetite control agents |
| WO2001090128A2 (en) * | 2000-05-24 | 2001-11-29 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the gpr3 gene |
| US7163800B2 (en) | 2000-11-03 | 2007-01-16 | Molecular Devices Corporation | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
| WO2002061087A2 (en) | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
| WO2002068579A2 (en) | 2001-01-10 | 2002-09-06 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
| US20030198627A1 (en) | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
| US20050118639A1 (en) * | 2002-02-22 | 2005-06-02 | Takeda Chemical Industries, Ltd | Method of determining ligand |
| WO2003097795A2 (en) * | 2002-05-13 | 2003-11-27 | Norak Biosciences, Inc. | Constitutively translocating cell line |
| JP4184875B2 (ja) * | 2002-06-14 | 2008-11-19 | 武田薬品工業株式会社 | 新規スクリーニング方法 |
| US20040023384A1 (en) * | 2002-07-31 | 2004-02-05 | Isis Pharmaceuticals Inc. | Antisense modulation of G protein-coupled receptor 12 expression |
| US20040023380A1 (en) * | 2002-07-31 | 2004-02-05 | Isis Pharmaceuticals Inc. | Antisense modulation of G protein-coupled receptor 6 expression |
| WO2004038407A2 (en) * | 2002-10-24 | 2004-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12) |
| AU2003301892A1 (en) | 2002-11-04 | 2004-06-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3) |
| AU2003224132A1 (en) | 2003-04-24 | 2004-11-19 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| EP1662862A1 (en) * | 2003-09-19 | 2006-06-07 | Paradigm Therapeutics Limited | Receptor |
| DK1745295T3 (da) * | 2004-04-20 | 2011-01-31 | Galapagos Nv | Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein |
-
2005
- 2005-04-20 DK DK05744241.0T patent/DK1745295T3/da active
- 2005-04-20 JP JP2007508855A patent/JP4890442B2/ja not_active Expired - Fee Related
- 2005-04-20 EP EP10174532A patent/EP2267458A3/en not_active Withdrawn
- 2005-04-20 EP EP05744241A patent/EP1745295B1/en not_active Expired - Lifetime
- 2005-04-20 AT AT05744241T patent/ATE483981T1/de active
- 2005-04-20 US US11/110,274 patent/US7429459B2/en not_active Expired - Fee Related
- 2005-04-20 SI SI200531166T patent/SI1745295T1/sl unknown
- 2005-04-20 EP EP10174529A patent/EP2270513A3/en not_active Withdrawn
- 2005-04-20 WO PCT/EP2005/004325 patent/WO2005103713A2/en not_active Ceased
- 2005-04-20 DE DE602005023976T patent/DE602005023976D1/de not_active Expired - Lifetime
- 2005-04-20 ES ES05744241T patent/ES2353604T3/es not_active Expired - Lifetime
- 2005-04-20 CA CA002605574A patent/CA2605574A1/en not_active Abandoned
-
2008
- 2008-08-13 US US12/190,888 patent/US7910320B2/en not_active Expired - Fee Related
-
2011
- 2011-02-01 US US13/019,057 patent/US20110118338A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2270513A2 (en) | 2011-01-05 |
| DK1745295T3 (da) | 2011-01-31 |
| EP1745295B1 (en) | 2010-10-06 |
| CA2605574A1 (en) | 2005-11-03 |
| WO2005103713A2 (en) | 2005-11-03 |
| JP4890442B2 (ja) | 2012-03-07 |
| JP2007533989A (ja) | 2007-11-22 |
| EP2267458A3 (en) | 2011-04-06 |
| ATE483981T1 (de) | 2010-10-15 |
| DE602005023976D1 (de) | 2010-11-18 |
| EP1745295A2 (en) | 2007-01-24 |
| EP2270513A3 (en) | 2011-04-06 |
| US7429459B2 (en) | 2008-09-30 |
| US20110118338A1 (en) | 2011-05-19 |
| US7910320B2 (en) | 2011-03-22 |
| US20090005262A1 (en) | 2009-01-01 |
| WO2005103713A3 (en) | 2006-09-08 |
| US20050266502A1 (en) | 2005-12-01 |
| ES2353604T3 (es) | 2011-03-03 |
| HK1099810A1 (en) | 2007-08-24 |
| EP2267458A2 (en) | 2010-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005108949A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| Fitzgerald et al. | Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson’s disease | |
| US10119168B2 (en) | Methods for the treatment of kidney fibrosis | |
| WO2009067546A3 (en) | Lung cancer markers and uses thereof | |
| McDonough et al. | Developing the next generation of cardiac markers: disease-induced modifications of troponin I | |
| JP2014506244A5 (enExample) | ||
| US20200232034A1 (en) | Methods of detecting osteoarthritis and predicting progression thereof | |
| Da Costa et al. | Transthyretin amyloidosis: chaperone concentration changes and increased proteolysis in the pathway to disease | |
| Xin et al. | Proteomics study reveals that the dysregulation of focal adhesion and ribosome contribute to early pregnancy loss | |
| ATE483981T1 (de) | Verfahren, zusammensetzungen und verbindungstests zur hemmung der amyloid-beta-proteinproduktion | |
| EA201491411A1 (ru) | Растворимый manf при поражениях бета-клеток поджелудочной железы | |
| WO2013023132A1 (en) | Diagnostic and prognostic markers for cancer | |
| ZA200807766B (en) | Inhibition of GASC1 | |
| MX2009001070A (es) | Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma. | |
| Xie et al. | Testosterone Delays Bone Microstructural Destruction via Osteoblast‐Androgen Receptor‐Mediated Upregulation of Tenascin‐C | |
| WO2005119262A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| WO2005103693A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| WO2006053251A3 (en) | Method of measuring amyloid-beta peptides | |
| WO2005103715A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| WO2005103692A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| WO2007095378A3 (en) | Mass tagging for quantitative analysis of biomolecules using 13c labeled phenylisocyanate | |
| Chen et al. | Effect of alanine replacement of L17 and F19 on the aggregation and neurotoxicity of arctic-type Aβ40 | |
| NO20053990L (no) | Assay for proteinisoformer | |
| EP1801232A4 (en) | METHOD FOR SCREENING A TRANSMEMBRANENZYMHEMMSTOFFS | |
| Vejayan et al. | The role of conventional two-dimensional electrophoresis (2DE) and its newer applications in the study of snake venoms |